@FierceBiotech: Proximagen polishes its CNS rep with $16M Lundbeck deal. News | Follow @FierceBiotech
@RyanMFierce: Which women in biotech inspire you? Please tell us here @FierceBiotech: Item | Follow @RyanMFierce
@MaureenFierce: U.S. economic woes "leading to risky Rx practices." People skimping on meds, MD visits. Piece | Follow @MaureenFierce
> Following the bitter commercial sales disappointments registered at Human Genome Sciences and Dendreon, investors and analysts are rethinking a common belief in the investment community. An approval, they say, no longer portends a steadily rising share price, as sticker shock on new biologics creates a market backlash they hadn't anticipated. Story
> Xconomy reports that Karuna Pharmaceuticals, a startup incubated at PureTech, has revealed more about its work on schizophrenia. The biotech in-licensed compounds from Vanderbilt which promise a new approach to treating the ailment. Story
> Portland, ME-based Putney has raised $21 million in a Series C designed to fund its work on generic pet drugs. Release
> After losing its fight to gain control of Actelion, Elliott Advisers has opted to cut its stake in the company to less than 3%. Story
Pharma News
@FiercePharma: Pfizer tells Indian hand-wringers that drug-price controls mean M&A won't touch off runaway price hikes $PFE #pharma. News | Follow @FiercePharma
> FDA hits Florida drugmakers with consent decree. Article
> After recalls, Merck sells out of J&J OTC venture for $175M. Report
> FDA slaps Sichuan on API facility shortfalls. News
> Hikma expects boost in Middle East health spending. Report
> GSK chief backs affordable pricing in India. Story
Vaccines News
> Gardasil bests Cervarix in cost effectiveness battle. News
> Vaccine could reduce HIV to 'minor infection.' Report
> Vaccines critical for controlling chronic diseases. Item
> Prospective Alzheimer's vax homes in on amyloid delivery. News
> Agenus encouraged by early HerpV results. Report
Manufacturing News
> GSK planning off-grid move for savings. Story
> Chinese API maker gets stern FDA warning over cross-contamination. Article
> The downside of downsizing: playing it safe. News
> Google AdWords ban keeps drug savings from U.S. poor. Report
> Congress gets started on drug-takeback program. Item
> Lean manufacturing lessons from Human Genome Sciences. Story
And Finally... In another sign of the growing scientific interest in hallucinogens, investigators at Johns Hopkins say that a careful study reveals that "magic mushrooms" can spur a lasting-positive-change in personality. Story